Alkermes PLC (NASDAQ:ALKS) has been assigned a $81.00 target price by stock analysts at Mizuho in a report released on Saturday. The firm presently has a “buy” rating on the stock. Mizuho’s target price suggests a potential upside of 60.14% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC set a $69.00 price target on shares of Alkermes PLC and gave the company a “buy” rating in a report on Friday, August 25th. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Barclays PLC lowered shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $66.00 to $50.00 in a report on Monday, October 16th. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $64.40.

Shares of Alkermes PLC (NASDAQ ALKS) traded up 0.04% during mid-day trading on Friday, reaching $50.58. 809,148 shares of the company were exchanged. Alkermes PLC has a 12 month low of $48.90 and a 12 month high of $63.40. The company’s 50 day moving average price is $51.19 and its 200 day moving average price is $55.28. The firm’s market capitalization is $7.77 billion.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The business had revenue of $218.80 million for the quarter, compared to analyst estimates of $216.54 million. During the same quarter in the previous year, the business earned ($0.01) earnings per share. The firm’s revenue was up 12.1% compared to the same quarter last year. Equities analysts anticipate that Alkermes PLC will post ($0.04) earnings per share for the current year.

WARNING: “Alkermes PLC (ALKS) Given a $81.00 Price Target at Mizuho” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/22/alkermes-plc-alks-given-a-81-00-price-target-at-mizuho.html.

In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $50.77, for a total value of $76,155.00. Following the transaction, the director now owns 9,500 shares in the company, valued at approximately $482,315. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Kathryn L. Biberstein sold 13,566 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the transaction, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,066 shares of company stock worth $930,280. Company insiders own 5.34% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank grew its position in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after acquiring an additional 212 shares in the last quarter. Daiwa SB Investments Ltd. bought a new stake in Alkermes PLC in the second quarter worth approximately $166,000. Greenwood Capital Associates LLC grew its position in Alkermes PLC by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after acquiring an additional 41 shares in the last quarter. US Bancorp DE grew its position in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after acquiring an additional 3,122 shares in the last quarter. Finally, Insight Capital Research & Management Inc. bought a new stake in Alkermes PLC in the second quarter worth approximately $232,000. 98.51% of the stock is owned by institutional investors.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Analyst Recommendations for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.